| scholarly article | Q13442814 |
| P50 | author | Henry Leonidas Gómez | Q43270076 |
| P2093 | author name string | George W Sledge | |
| Shona Nag | |||
| Louis W C Chow | |||
| Dinesh C Doval | |||
| Zeba Aziz | |||
| Miguel A Chavez | |||
| Christina Ng | |||
| Mark S Berger | |||
| Michael C Arbushites | |||
| Michelle A Casey | |||
| Peter C-S Ang | |||
| Sandra X Franco | |||
| Steven H Stein | |||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2999-3005 | |
| P577 | publication date | 2008-05-05 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer | |
| P478 | volume | 26 |
| Q33587404 | A 3D in vitro model of the human breast duct: a method to unravel myoepithelial-luminal interactions in the progression of breast cancer |
| Q43120670 | A Validated RP-HPLC Method for the Estimation of Lapatinib in Tablet Dosage form using Gemcitabine Hydrochloride as an Internal Standard |
| Q34611637 | A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas |
| Q35597532 | A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies |
| Q34530485 | A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies |
| Q36095920 | A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer |
| Q37357251 | A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer |
| Q45812913 | A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer |
| Q36247858 | Activated estrogen receptor-mitogen-activated protein kinases cross talk confer acquired resistance to lapatinib |
| Q30758991 | Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial |
| Q89715652 | Administration of Lapatinib with Food Increases Its Plasma Concentration in Chinese Patients with Metastatic Breast Cancer: A Prospective Phase II Study |
| Q35989963 | Advances in first-line treatment for patients with HER-2+ metastatic breast cancer |
| Q33777427 | An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. |
| Q37158137 | Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer |
| Q39689222 | Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. |
| Q33575434 | Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model |
| Q35588268 | BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. |
| Q37788248 | Biological considerations and clinical applications of new HER2-targeted agents |
| Q83457870 | Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib |
| Q38068491 | Bringing cancer serological diagnosis to a new level: focusing on HER2, protein ectodomain shedding and neoepitope technology. |
| Q48212195 | Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis. |
| Q38825945 | Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer |
| Q35625995 | Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. |
| Q37356307 | Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer |
| Q37573906 | Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast Cancer |
| Q37765198 | Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel |
| Q36585794 | Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function |
| Q39389259 | Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence |
| Q54389879 | Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. |
| Q36250585 | Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence |
| Q34427231 | Efficacy of lapatinib monotherapy on occult breast cancer presenting with cutaneous metastases: A case report |
| Q57142532 | Emerging drugs in metastatic breast cancer |
| Q37961957 | Emerging drugs in metastatic breast cancer: an update |
| Q34611634 | Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal |
| Q37698914 | Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells |
| Q41617336 | Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway |
| Q58849503 | Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer |
| Q37970020 | ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective |
| Q33561588 | Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme |
| Q48461764 | Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience |
| Q28252845 | Factors underlying sensitivity of cancers to small-molecule kinase inhibitors |
| Q100426629 | From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm |
| Q36226540 | Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines |
| Q57137333 | HER2 and hormone receptor-positive breast cancer--blocking the right target |
| Q37705396 | HER2 as a target for breast cancer therapy. |
| Q37303196 | HER2 breast cancer therapies: a review |
| Q34974436 | HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies |
| Q39034850 | HER2-positive breast cancer |
| Q37826199 | Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? |
| Q54599560 | Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. |
| Q38125970 | Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. |
| Q34627179 | Hunk is required for HER2/neu-induced mammary tumorigenesis |
| Q33648150 | Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models |
| Q34651354 | Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines |
| Q43629693 | Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients |
| Q35949304 | Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer |
| Q35599781 | Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer. |
| Q85857386 | Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation |
| Q38728508 | Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer |
| Q33936071 | It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy |
| Q37338235 | Jumping higher: is it still possible? The ALTTO trial challenge |
| Q50419862 | Kernelized rank learning for personalized drug recommendation. |
| Q37578368 | LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer |
| Q97644226 | Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells |
| Q27342948 | Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor |
| Q54469155 | Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. |
| Q37782086 | Lapatinib and breast cancer: current indications and outlook for the future |
| Q37810946 | Lapatinib for breast cancer: a review of the current literature |
| Q37815620 | Lapatinib in breast cancer: clinical experiences and future perspectives |
| Q37622978 | Lapatinib in metastatic breast cancer. |
| Q37396923 | Lapatinib induces p27(Kip1)-dependent G₁ arrest through both transcriptional and post-translational mechanisms |
| Q37424096 | Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. |
| Q37677684 | Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience |
| Q54404133 | Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO). |
| Q33579653 | Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. |
| Q37628693 | Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer. |
| Q34993721 | Lapatinib-induced hepatitis: a case report. |
| Q37605777 | Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer |
| Q38992588 | Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer |
| Q37355729 | Lapatinib: new opportunities for management of breast cancer |
| Q34241118 | Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib |
| Q37725973 | Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends |
| Q38570532 | Management of pulmonary toxicity associated with targeted anticancer therapies |
| Q28080497 | Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib |
| Q35002433 | Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib |
| Q53078543 | Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. |
| Q28072513 | Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer |
| Q37660907 | Molecular predictors of response to trastuzumab and lapatinib in breast cancer. |
| Q37144315 | New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available |
| Q38152742 | Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations |
| Q37491455 | Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients |
| Q38017732 | Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. |
| Q55012187 | PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. |
| Q90528249 | Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity |
| Q38132237 | Pertuzumab for the treatment of metastatic breast cancer |
| Q42598708 | Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. |
| Q38024126 | Pharmacologic modulation strategies to reduce dose requirements of anticancer therapy while preserving clinical efficacy. |
| Q34440220 | Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors |
| Q35947019 | Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomogr |
| Q51534056 | Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. |
| Q41134799 | Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer |
| Q38835374 | Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib |
| Q37417742 | Protein kinase inhibitors: contributions from structure to clinical compounds |
| Q34272887 | Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis |
| Q36704672 | Psoriasis aggravation due to lapatinib |
| Q27015506 | Quantification of HER family receptors in breast cancer |
| Q34551761 | Resiliency and vulnerability in the HER2-HER3 tumorigenic driver |
| Q35591518 | Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications |
| Q51016839 | Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab. |
| Q37355762 | Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer |
| Q34417920 | Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. |
| Q39557421 | Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. |
| Q43599415 | Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study |
| Q37380452 | Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens |
| Q37422695 | Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells |
| Q89529557 | Synergistic Antitumor Effects on Drug-Resistant Breast Cancer of Paclitaxel/Lapatinib Composite Nanocrystals |
| Q35871467 | Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group |
| Q38575259 | Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here? |
| Q38209463 | Systemic treatment of HER2-positive metastatic breast cancer: a systematic review. |
| Q39207632 | TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line |
| Q37851009 | Taming the dragon: genomic biomarkers to individualize the treatment of cancer. |
| Q90862850 | Targeted therapeutic options and future perspectives for HER2-positive breast cancer |
| Q37633006 | Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways |
| Q45988803 | Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer. |
| Q42571051 | Targeted therapy in HER2-positive breast cancer |
| Q34363419 | Targeted treatment of advanced and metastaticbreast cancer with lapatinib. |
| Q37326072 | The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies |
| Q37937923 | The role of chemotherapy and targeted agents in patients with metastatic breast cancer |
| Q47331018 | The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. |
| Q34570753 | Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer |
| Q38052616 | Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients |
| Q47795804 | Trastuzumab emtansine: determining its role in management of HER2+ breast cancer |
| Q37387449 | Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer |
| Q37632118 | Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. |
| Q36275971 | Treatment of HER2-positive metastatic breast cancer following initial progression |
| Q37772792 | Treatment strategy for HER2-positive breast cancer |
| Q36134545 | Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy |
| Q33597963 | What is known about melatonin, chemotherapy and altered gene expression in breast cancer |
| Q83901136 | [Tyrosine kinase inhibitors in oncology] |
Search more.